Evogene Ltd. (NASDAQ:EVGN) Q4 2019 Earnings Conference Call March 4, 2020 9:00 AM ET Company Participants Ofer Haviv – Chief Executive Officer Dorit Kreiner – Chief Financial Officer Conference Call Participants David Draiman – Draiman Asset Management Operator Ladies and gentlemen, thank you for standing by. Welcome to Evogene’s Fourth Quarter and Full Year 2019 Results Conference Call. All participants are present in a listen-only mode. Following management’s formal presentation, instructions will be give ...

Evogene Ltd. (NASDAQ:EVGN) Q3 2019 Earnings Conference Call November 13, 2019 9:00 AM ET Company Participants Ofer Haviv – Chief Executive Officer Elran Haber – Chief Executive Officer-Biomica Dorit Kreiner – Chief Financial Officer Conference Call Participants David Dreman – Dreman Asset Management Operator Ladies and gentlemen, thank you for standing by. Welcome to EvogeneÂ's Third Quarter 2019 Results Conference Call. All participants are present in a listen-only mode. Following managementÂ's formal pres ...

August, 2019 EVOGENE AT A GLANCE… Ofer Haviv, President & CEO SAFE HARBOR STATEMENT This presentation contains "forward-looking statements" relating to future events, and we may from time to time make other statements, regarding our outlook or expectations for future financial or operating results and/or other matters regarding or affecting Evogene Ltd. or its subsidiaries (collectively, "Evogene" or "we"), that are considered "forward-looking statements" as defined in the U.S. Private Securities Litigation ...

Financial Data and Key Metrics Changes - As of June 30, 2019, the company maintained approximately $46 million in cash and cash-related accounts, with cash usage of approximately $8.7 million in the first half of 2019 and $4.2 million in the second quarter of 2019 [36] - The gross profit for the first half of 2019 was approximately $0.4 million, compared to approximately $0.2 million for the same period in 2018, while the gross profit for the second quarter of 2019 remained stable at approximately $0.1 million [39] - The loss for the first half of 2019 decreased to $7.9 million compared to a loss of $10.1 million during the first half of 2018, and the loss for the second quarter of 2019 decreased to $4.1 million compared to a loss of $4.8 million in the second quarter of 2018 [43] Business Line Data and Key Metrics Changes - The company has established subsidiaries focused on agriculture, human health, and life-science based industrial applications, with specific subsidiaries like Lavie Bio focusing on bio-stimulants and bio-pesticides [9][10] - Lavie Bio reported positive second-year field results in its bio-stimulant program for wheat, showing significant yield improvement across multiple locations and conditions [22] Market Data and Key Metrics Changes - The agriculture market is shifting towards consumer-driven demand for sustainable practices, health, and quality of produce, which is influencing the development of ag-biological products [26] - The company identified spring wheat as a high commercial value crop, with a market of over 25 million acres in North America, allowing for independent go-to-market strategies [30] Company Strategy and Development Direction - The company aims to support its subsidiaries in accelerating product development towards commercialization, leveraging its unique computational technological capabilities through the CPB platform [7][12] - Evogene intends to remain a major stakeholder in its subsidiaries following any external fundraising to maintain a significant share of future profits and market value [19] Management's Comments on Operating Environment and Future Outlook - Management highlighted the importance of technological, corporate, and funding support for subsidiaries to achieve their strategic plans and product development milestones [12][16] - The company plans to financially support its subsidiaries until they reach maturity and can generate revenues or secure external funding [18] Other Important Information - The company amended its plant disease collaboration agreement with Bayer to include genome editing targets, following positive results in corn stalk rot fungal disease control [21] - The company has initiated dedicated fundraising processes for several subsidiaries to meet their financial requirements for achieving milestone roadmaps [20] Q&A Session Summary - The call concluded without any recorded questions or answers, indicating a lack of engagement during the Q&A segment [44][45]

Company Overview - Evogene aims to revolutionize product development in life-science markets using its Computational Predictive Biology (CPB) platform[6, 28] - The CPB platform utilizes AI and big data to predict candidates addressing product criteria early in development[13, 29] - Evogene's CPB platform is applied across various markets including Agriculture, Human Health, and Industrial Applications[19, 24] - The company has a corporate structure with subsidiaries focused on specific life-science markets, each with exclusive access to the CPB platform[23, 30] Financial Highlights - As of June 30, 2019, Evogene's cash position was approximately $46 million[31, 76] - The estimated net cash usage for 2019 is projected to be between $16 million and $18 million[76] - The company has no debt and is listed on both TASE (2007) and NASDAQ (2013)[31, 76] - In the first half of 2019, Evogene reported revenues of $540 thousand[77] - The operating loss for the first half of 2019 was $(9,372) thousand[77]

Evogene Ltd. (NASDAQ:EVGN) Q1 2019 Earnings Conference Call May 28, 2019 9:00 AM ET Company Participants Ofer Haviv - CEO Arnon Heyman - CEO, Canonic Dorit Kreiner - CFO Conference Call Participants Operator Ladies and gentlemen, thank you for standing by. Welcome to Evogene's First Quarter 2019 Results Conference Call. All participants are at present in listen-only mode. Following management's formal presentation, instructions will be given for the question-and-answer session. [Operator Instructions] As a ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 20-F ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2018 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☐ SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commissi ...